Liquidia to Present at Upcoming Investor Conferences
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, from 11:00 to 11:35 a.m. ET, and at the 2024 Cantor Global Healthcare Conference in New York on September 19, from 1:30 to 1:50 p.m. ET.
Investors and interested parties can access the webcasts of these presentations through Liquidia's website. Recorded versions of the presentations will be available on the company's website for at least 30 days following each event, providing an opportunity for those unable to attend live to review the information presented.
Liquidia (NASDAQ: LQDA), un'azienda biofarmaceutica focalizzata su malattie cardiopolmonari rare, ha annunciato la sua partecipazione a due conferenze per investitori in programma a settembre 2024. L'azienda presenterà al 2024 Wells Fargo Healthcare Conference a Boston il 5 settembre, dalle 11:00 alle 11:35 ora ET, e al 2024 Cantor Global Healthcare Conference a New York il 19 settembre, dalle 13:30 alle 13:50 ora ET.
Investitori e parti interessate possono accedere alle dirette streaming di queste presentazioni tramite il sito web di Liquidia. Le versioni registrate delle presentazioni saranno disponibili sul sito dell'azienda per almeno 30 giorni dopo ciascun evento, offrendo l'opportunità a coloro che non possono partecipare dal vivo di rivedere le informazioni presentate.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica centrada en enfermedades cardiopulmonares raras, ha anunciado su participación en dos conferencias para inversores que se celebrarán en septiembre de 2024. La empresa presentará en la 2024 Wells Fargo Healthcare Conference en Boston el 5 de septiembre, de 11:00 a 11:35 a.m. ET, y en la 2024 Cantor Global Healthcare Conference en Nueva York el 19 de septiembre, de 1:30 a 1:50 p.m. ET.
Los inversores y partes interesadas pueden acceder a las retransmisiones web de estas presentaciones a través del sitio web de Liquidia. Las versiones grabadas de las presentaciones estarán disponibles en el sitio de la empresa durante al menos 30 días después de cada evento, proporcionando una oportunidad para aquellos que no puedan asistir en vivo de revisar la información presentada.
리퀴디아 (NASDAQ: LQDA), 희귀 심폐 질환에 주력하는 생명공학 회사는 2024년 9월에 개최되는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 9월 5일 오전 11시부터 11시 35분(ET)까지 보스턴에서 열리는 2024 웰스 파고 헬스케어 컨퍼런스에서 발표할 예정이며, 9월 19일 오후 1시 30분부터 1시 50분(ET)까지 뉴욕에서 열리는 2024 칸토 글로벌 헬스케어 컨퍼런스에서도 발표할 예정입니다.
투자자 및 이해관계자는 리퀴디아의 웹사이트를 통해 이러한 프레젠테이션의 웹캐스트에 접근할 수 있습니다. 각 이벤트 후 최소 30일 동안 회사를 통해 발표 내용의 녹화된 버전을 이용할 수 있어, 직접 참석할 수 없는 사람들도 정보를 검토할 수 있는 기회를 제공합니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur les maladies cardiopulmonaires rares, a annoncé sa participation à deux conférences d'investisseurs à venir en septembre 2024. L'entreprise présentera à la 2024 Wells Fargo Healthcare Conference à Boston le 5 septembre, de 11h00 à 11h35 (ET), et à la 2024 Cantor Global Healthcare Conference à New York le 19 septembre, de 13h30 à 13h50 (ET).
Les investisseurs et les parties intéressées peuvent accéder aux rediffusions de ces présentations via le site web de Liquidia. Les versions enregistrées des présentations seront disponibles sur le site de l'entreprise pendant au moins 30 jours après chaque événement, offrant une opportunité à ceux qui ne peuvent pas assister en direct de revoir les informations présentées.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf seltene kardiopulmonale Erkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Das Unternehmen wird am 5. September von 11:00 bis 11:35 Uhr ET auf der 2024 Wells Fargo Healthcare Conference in Boston präsentieren und am 19. September von 13:30 bis 13:50 Uhr ET auf der 2024 Cantor Global Healthcare Conference in New York.
Investoren und Interessierte können die Webcasts dieser Präsentationen über die Website von Liquidia abrufen. Aufgezeichnete Versionen der Präsentationen werden für mindestens 30 Tage nach jeder Veranstaltung auf der Unternehmenswebsite verfügbar sein, sodass diejenigen, die nicht live teilnehmen können, die präsentierten Informationen überprüfen können.
- None.
- None.
MORRISVILLE, N.C., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the following investor conferences this September:
- 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, from 11:00 – 11:35 a.m. ET
- 2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, from 1:30 – 1:50 p.m. ET
Access to the webcasts will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations.
An archived, recorded version of each presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
FAQ
When and where is Liquidia (LQDA) presenting at investor conferences in September 2024?
How can investors access Liquidia's (LQDA) presentations at the September 2024 conferences?
How long will Liquidia's (LQDA) September 2024 conference presentations be available online?
What is the focus of Liquidia (LQDA)?
